Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovoCure reports positive Phase 2 pancreatic cancer trial, 74% disease control vs. 48% standard
Filed March 26, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
high
PANOVA-4 trial met primary endpoint: 74.4% disease control rate with TTFields plus immunotherapy and chemo versus 48% with chemo alone (p<0.001), a 26.4 percentage point improvement in metastatic pancreatic cancer patients.
Item 7.01 Press Release verify on EDGAR → -
high
Trial tested TTFields as first-line treatment for metastatic pancreatic ductal adenocarcinoma, a difficult-to-treat cancer, potentially opening a new indication beyond NovoCure's current approved uses.
Item 7.01 Press Release verify on EDGAR → -
medium
Results compare favorably to historical control from Phase 3 MPACT study (N=431 patients on standard chemotherapy), with statistical significance supporting potential efficacy of the combination approach.
Item 7.01 Press Release verify on EDGAR →
Summary
NovoCure announced that its Phase 2 PANOVA-4 trial met its primary endpoint, showing a 74.4% disease control rate in metastatic pancreatic cancer patients treated with TTFields therapy combined with atezolizumab immunotherapy and standard chemotherapy.
This compares to a 48% control rate in patients receiving chemotherapy alone in a historical control study, representing a statistically significant 26.4 percentage point improvement. For retail investors, this matters because pancreatic cancer is notoriously difficult to treat and has limited therapeutic options.
A positive Phase 2 result could open a significant new market for NovoCure's TTFields technology beyond its current glioblastoma indication. The company enrolled 78 patients in this arm of the trial, and the statistical significance (p<0.001) suggests the results are unlikely due to chance. Watch for NovoCure's next steps: whether they advance to Phase 3 trials, seek regulatory guidance, or partner with the immunotherapy manufacturer. Also monitor whether the company releases survival data, as disease control rate is an intermediate endpoint—overall survival would be the ultimate measure of clinical benefit.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
NovoCure filed an 8-K attaching a press release dated March 26, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release of NovoCure Limited, dated March 26, 2026
The 8-K references an attached press release dated March 26, 2026. The filing body does not disclose the content or subject matter of the press release, so the nature and materiality of the announcement cannot be determined from this 8-K alone. Investors should review Exhibit 99.1 directly to understand what was announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify